替吉奥联合奥沙利铂治疗晚期胃癌伴肝转移的疗效及对患者血清基质金属蛋白酶9、血管内皮生长因子的影响  

Effect of tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin on advanced gastric cancer with liver metastasis and its influence on serum matrix metalloproteinase 9 and vascular endothelial growth factor

作　　者：吴共国 林俊[1] Wu Gongguo;Lin Jun(Department of Oncology,the Second People's Hospital of Jiande,Jiande,Zhejiang 311604,China)

机构地区：[1]建德市第二人民医院肿瘤内科,浙江省311604

出　　处：《中国基层医药》2019年第1期48-51,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨替吉奥联合奥沙利铂治疗晚期胃癌伴肝转移患者的临床疗效及其对患者血清基质金属蛋白酶9、血管内皮生长因子的影响。方法选取2012年1月至2017年2月建德市第二人民医院收治的晚期胃癌伴肝转移患者125例,采用随机数字表法分为对照组63例、观察组62例。对照组采用替吉奥治疗;观察组采用替吉奥联合奥沙利铂治疗。评价两组临床疗效,记录治疗期间不良反应,分别于治疗前、后检测两组血清基质金属蛋白酶9(MMP-9)、血管内皮生长因子(VEGF)水平。结果观察组总有效率80.64%(50/62),明显高于对照组的57.14%(36/63)(χ^2=8.294,P=0.015);观察组不良反应发生率22.58%(14/62),明显低于对照组的47.61%(30/63)(χ^2=8.588,P=0.003)。两组患者治疗后MMP-9、VEGF水平均明显低于治疗前(均P=0.000),观察组治疗后MMP-9、VEGF水平均明显低于对照组(t=14.203、1.560,P=0.000、0.000)。结论替吉奥联合奥沙利铂治疗晚期胃癌伴肝转移疗效显著且不良反应少,并可降低MMP-9、VEGF水平。Objective To investigate the clinical efficacy of tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of patients with advanced gastric cancer and liver metastases. Methods From January 2012 to February 2017, 125 patients with advanced gastric cancer and liver metastases in the Second People's Hospital of Jiande were selected and randomly divided into control group and observation group.The control group(63 cases) was treated with tegafur, gimeracil and oteracil porassium capsules.The observation group(62 cases) was treated with tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin.The clinical efficacy of the two groups was evaluated, and the adverse reactions during the treatment were recorded.The serum levels of matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) were measured before and after treatment. Results The total effective rate of the observation group was 80.64%(50/62), which was significantly higher than 57.14%(36/63) of the control group (χ^2=8.294, P=0.015). The incidence rate of adverse reaction in the observation group was 22.58%(14/62), which was significantly lower than 47.61%(30/63) in the control group (χ^2=8.588, P=0.003). After treatment, the levels of MMP-9 and VEGF in the two groups were significantly lower than those before treatment (all P=0.000). The MMP-9 and VEGF levels in the observation group were significantly lower than those in the control group(t=14.203, 1.560, P=0.000, 0.000). Conclusion The efficacy of tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of advanced gastric cancer with liver metastasis is significant and has less adverse reactions.

关 键 词：胃肿瘤 肿瘤转移 基质金属蛋白酶9 血管内皮生长因子类 抗肿瘤联合化疗方案 替吉奥 奥沙利铂 

分 类 号：R735.2[医药卫生—肿瘤]